Get the Stockscreener App
1.49
1.36%
0.02
After Hours:
1.54
0.05
+3.36%
Pliant Therapeutics Inc stock is traded at $1.49, with a volume of 689.38K.
It is up +1.36% in the last 24 hours and down -6.29% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.47
Open:
$1.46
24h Volume:
689.38K
Relative Volume:
0.85
Market Cap:
$91.47M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4822
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+0.00%
1M Performance:
-6.29%
6M Performance:
+11.19%
1Y Performance:
-89.08%
1-Day Range:
$1.46
$1.53
1-Week Range:
$1.45
$1.59
52-Week Range:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.49 | 90.24M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Can Pliant Therapeutics Inc. stock maintain operating marginsJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pliant Therapeutics Inc. stock trend forecast2025 Investor Takeaways & Capital Efficiency Focused Strategies - newser.com
Has Pliant Therapeutics Inc. found a price floorJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
What to expect from Pliant Therapeutics Inc. in the next 30 daysJuly 2025 Decliners & Consistent Growth Equity Picks - newser.com
Will Pliant Therapeutics Inc. bounce back from current supportJuly 2025 PostEarnings & Community Consensus Trade Alerts - newser.com
Price momentum metrics for Pliant Therapeutics Inc. explainedJuly 2025 Breakouts & Free Community Consensus Stock Picks - newser.com
Can you recover from losses in Pliant Therapeutics Inc.Volume Spike & Weekly Watchlist of Top Performers - newser.com
What analysts say about Pliant Therapeutics Inc stockDividend Cut Warnings & Low Risk Investment Plans - earlytimes.in
Pliant Therapeutics' (PLRX) Underweight Rating Reiterated at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Pliant Therapeutics stock rating to Underweight from Neutral - Investing.com Canada
Pliant Therapeutics Shares Fall After JPMorgan Downgrade - MarketScreener
Pliant Therapeutics Inc. stock outlook for YEARMarket Growth Review & Capital Protection Trade Alerts - newser.com
Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha
JPMorgan Downgrades Pliant Therapeutics to Underweight From Neutral - MarketScreener
PLRX Downgraded by JP Morgan: Today's Key Analyst Rating Update - GuruFocus
Order flow analysis tools used on Pliant Therapeutics Inc.July 2025 Intraday Action & Community Consensus Stock Picks - newser.com
Pliant Therapeutics (NASDAQ:PLRX) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Does Pliant Therapeutics Inc. stock trade at a discount to peersTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Is Pliant Therapeutics Inc. (9PT) stock testing key supportPortfolio Growth Summary & Accurate Buy Signal Notifications - newser.com
Is Pliant Therapeutics Inc. (9PT) stock a top pick for value investorsGlobal Markets & Free Reliable Trade Execution Plans - newser.com
Detecting price anomalies in Pliant Therapeutics Inc. with AIJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Evaluating Pliant Therapeutics Inc. with trendline analysis2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Why Pliant Therapeutics Inc. (9PT) stock attracts wealthy investorsJuly 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com
How sustainable is Pliant Therapeutics Inc. stock dividend payoutJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-03 01:17:50 - newser.com
How Pliant Therapeutics Inc. (9PT) stock reacts to new regulationsEarnings Recap Report & Consistent Return Strategy Ideas - newser.com
Applying big data sentiment scoring on Pliant Therapeutics Inc.Gold Moves & Low Risk High Reward Trade Ideas - newser.com
Technical analysis overview for Pliant Therapeutics Inc. stockQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Will Pliant Therapeutics Inc. (9PT) stock keep raising dividendsQuarterly Portfolio Report & Trade Opportunity Analysis - newser.com
Visualizing Pliant Therapeutics Inc. stock with heatmaps2025 Trade Ideas & Expert Verified Stock Movement Alerts - newser.com
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):